SecBot SecBot

FHTX drug pipeline

$1.79
−13.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketUnknown — the drug is in early Phase 1 dose-escalation. Assuming successful development, a potential approval would be several years away (likely 2029+).

FHD-909 Updated Sep 4

What to watch

Monitor for any announced Phase 1 data readout date or interim results from the FHD-909 dose-escalation trial, which would be the next major catalyst. Also watch the December 2026 Lilly collaboration term expiration for potential restructuring or milestone news. The stock's ~144% implied upside to analyst targets reflects optimism about the platform, but early-stage clinical risk remains substantial.

Bull case
  • Preclinical data at AACR 2026 showed complete and durable tumor regression with FHD-909 + anti-PD-1 combination, plus anti-tumor immune memory, a strong signal for a differentiated mechanism in SMARCA4-mutant NSCLC.
  • Analyst consensus is Strong Buy (15 Buy/Strong Buy vs 1 Hold) with a mean price target of $11.44, implying ~144% upside from the current ~$4.92 price.
  • FHD-909 is partnered with Eli Lilly (code LY4050784), providing validation and potential milestone/revenue support; Foghorn had $167.6M cash as of Q2 2026 with runway into H1 2028.
Bear case
  • FHD-909 is in early Phase 1 dose-escalation, no human efficacy data yet; preclinical results often fail to translate to patients.
  • The Lilly collaboration research term expires in December 2026, creating a potential revenue cliff and uncertainty about future partnership terms.
  • Foghorn's CBPd-171 (FHT-171) program was delayed due to a CRO operational issue, raising concerns about broader execution risk.